静脉铁剂市场规模、份额、成长分析、按产品类型、按适应症、按分销管道、按地区 - 产业预测，2025-2032 年

2023年静脉注射铁剂市场规模为32亿美元，从2024年的34.7亿美元成长到2032年的66.1亿美元，预计复合年增长率为8.4%。

全球静脉铁剂市场正在经历显着成长，这主要是由于缺铁性贫血盛行率不断上升，影响了很大一部分人口。缺铁性贫血会导致携氧能力下降，导致疲劳和认知功能障碍等症状。人口老化进一步推动市场需求，因为老年人由于饮食限制和慢性病等因素更容易缺铁。静脉铁剂治疗提供了口服补充品的有效替代方案，可确保快速缓解症状并改善患者的治疗效果。市场开发公司在研发方面投入巨资，以开发创新配方并提高安全性，并进行策略合作以扩大其产品线和市场范围。随着意识和需求的增加，市场有望继续扩大。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

静脉注射铁剂市场规模：依产品类型划分

• 市场概况
• 聚葡萄糖铁
• 蔗糖铁
• Ferric carboxymaltose
• 其他产品类型

静脉铁剂市场规模：依适应症分类

• 市场概况
• 慢性肾臟病
• 发炎性肠道疾病
• 癌症
• 其他疾病

静脉铁剂市场规模：依通路划分

• 市场概况
• 医院药房
• 零售药房
• 网路药房

静脉铁剂市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Sanofi（France）
• Pharmacosmos A/S（Denmark）
• AbbVie Inc.（United States）
• Daiichi Sankyo Company, Ltd.（Japan）
• Pfizer Inc.（United States）
• Zydus Lifesciences Limited（India）
• Fresenius SE & Co. KGaA（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Akebia Therapeutics, Inc.（United States）
• Rockwell Medical, Inc.（United States）
• American Regent, Inc.（United States）
• AdvaCare Pharma（United States）
• Bayer AG（Germany）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Novartis AG（Switzerland）
• Shield Therapeutics plc（United Kingdom）
• Galenica Ltd.（Switzerland）
• CSL Limited（Australia）
• AMAG Pharmaceuticals, Inc.（United States）
• Covis Pharma GmbH（Switzerland）

结论和建议

Intravenous Iron Drugs Market size was valued at USD 3.2 Billion in 2023 and is poised to grow from USD 3.47 Billion in 2024 to USD 6.61 Billion by 2032, growing at a CAGR of 8.4% during the forecast period (2025-2032).

The global intravenous iron drugs market is witnessing significant growth, primarily driven by the rising incidence of iron deficiency anemia, which affects a considerable portion of the population. This condition leads to decreased oxygen-carrying capacity, resulting in symptoms like fatigue and cognitive impairment. The aging demographic further fuels market demand, as older adults are more prone to iron deficiency due to factors such as dietary limitations and chronic illnesses. Intravenous iron therapy provides an efficient alternative to oral supplements, ensuring quicker relief and better patient outcomes. Market players are investing heavily in research and development to create innovative formulations and enhance safety, collaborating strategically to broaden their product lines and market reach. As awareness and demand increase, the market is poised for continued expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Intravenous Iron Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Intravenous Iron Drugs Market Segmental Analysis

Global Intravenous Iron Drugs Market is segmented by product type, indication, distribution channel and region. Based on product type, the market is segmented into Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Other Product Types. Based on indication, the market is segmented into Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Diseases. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Intravenous Iron Drugs Market

The intravenous iron drugs market is significantly driven by the rising incidence of iron deficiency anemia globally. This condition is particularly prevalent among specific groups, including pregnant women, women of childbearing age, and individuals suffering from chronic illnesses. As awareness regarding the serious implications of iron deficiency continues to grow, coupled with the proven efficacy of intravenous iron therapies in effectively addressing this issue, there has been an upsurge in demand for these treatments. This heightened recognition and the ongoing need for effective solutions to combat iron deficiency anemia are key factors propelling the expansion of the intravenous iron drugs market.

Restraints in the Intravenous Iron Drugs Market

One significant restraint affecting the intravenous iron drugs market is the potential for adverse reactions or side effects during administration. Although these drugs are largely regarded as safe, the possibility of hypersensitivity reactions and infusion-related complications exists, including allergic responses, hypotension, and anaphylaxis. The fear of these adverse events may dissuade both healthcare professionals and patients from opting for intravenous iron therapy, thus restricting market growth. To address this challenge, it is crucial for manufacturers and healthcare providers to implement stringent patient selection criteria, effective monitoring, and careful administration protocols, all aimed at reducing the risk of complications and ensuring patient safety.

Market Trends of the Intravenous Iron Drugs Market

The intravenous iron drugs market is witnessing a significant trend towards innovation, characterized by the development of enhanced iron formulations designed to improve safety, efficacy, and patient convenience. Pharmaceutical companies are heavily investing in research to create advanced intravenous therapies that mitigate the drawbacks of traditional iron supplements, focusing on features such as extended dosing intervals, better tolerability, and minimized hypersensitivity risks. This shift not only enhances patient compliance but also marks a commitment to improving overall treatment outcomes. The ongoing push for novel formulations underscores a growing emphasis on patient-centric care within the intravenous iron drugs market, driving its growth and evolution.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Intravenous Iron Drugs Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Other Product Types

Global Intravenous Iron Drugs Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Other Diseases

Global Intravenous Iron Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Intravenous Iron Drugs Market Size & CAGR (2025-2032)

• North America (Product Type, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmacosmos A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rockwell Medical, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• American Regent, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AdvaCare Pharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shield Therapeutics plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galenica Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AMAG Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covis Pharma GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations